Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Want to see OVID full AI Analyst Report?
OVID Stock Chart & Stats
$2.91
-$0.03(-2.93%)
At close: 4:00 PM EST
$2.91
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.27 - $3.11
Previous CloseN/A
Volume22.63K
Average Volume (3M)4.61M
Market Cap
$363.97M
Enterprise Value$439.76M
Total Cash (Recent Filing)$69.64M
Total Debt (Recent Filing)$13.42M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
May 13, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding131,874,630
10 Day Avg. Volume4,166,385
30 Day Avg. Volume4,606,238
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue60.64
Enterprise Value/Gross Profit61.15
Enterprise Value/Ebitda-10.52
Forecast
1Y Price Target
$5.03Price Target Upside72.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$254.38K
Bulls Say, Bears Say
Bulls Say
Biomarkers And Trial DesignAnalyst notes that planned use of electroencephalography and event-related potential biomarkers in early human studies can enable efficient assessment of target engagement and mechanism before moving to indication-specific trials.
Preclinical Efficacy And Therapeutic BreadthAnalyst emphasizes compelling preclinical efficacy of KCC2 activators across models of psychosis, anxiety, seizures, and pain, suggesting a broad therapeutic opportunity if clinical proof-of-concept is achieved.
Safety And Early Human SignalsAnalyst highlights that OV329 produced favorable safety and tolerability with no retinal findings alongside clear on-target biomarker responses in healthy volunteer studies, supporting advancement toward efficacy testing in seizure disorders.
Bears Say
Clinical Development Risk And Valuation UncertaintyAnalyst warns that KCC2 remains an early-stage mechanism not included in current valuation, creating uncertainty for investors until human proof-of-concept is demonstrated.
Financing And Dilution RiskAnalyst cautions that company funding depends on future financing and on exercise or expiry of Series A warrants, which could lead to equity dilution or funding pressure.
Regulatory Ocular Toxicity UncertaintyAnalyst notes regulatory risk tied to overturning historical class warnings on ocular toxicity, which would require robust, specific clinical data to resolve and could impede approval if not addressed.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.27 and its highest was $3.10 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $363.97M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is May 13, 2026 which is in 24 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Mar 18, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.117 by $0.177.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 131,874,630 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.117. Following the earnings report the stock price went up 14.428%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.03 (72.85% Upside)
$5.03 (72.85% Upside)
Blogger Sentiment
Bullish
OVID Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 9.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 9.6%
Last 30 Days ▲ 9.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
910.41%
12-Months-Change
Fundamentals
Return on Equity
-23.98%
Trailing 12-Months
Asset Growth
63.76%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Company Deck
OVID Earnings Call
Q4 2026
0:00 / 0:00
OVID Stock 12 Month Forecast
Average Price Target
$5.03
▲(72.85% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
9.88% Insiders
9.09% Mutual Funds
0.01% Other Institutional Investors
78.75% Public Companies and
Individual Investors